Cantai Therapeutics
Cantai Therapeutics is a startup headquartered in Philadelpia, United States, founded in 2023. It has raised at least $4.2m in outside funding, according to its filings with the US Securities and Exchange Commission (Form D), which puts it at the seed stage.
Part of the 311 Institute Global Startups Directory (311institute.com). Last updated .
Funding
Cantai Therapeutics has raised at least $4.2m in outside funding, according to its Form D filings with the US Securities and Exchange Commission. Form D figures are a minimum: not every round is filed.
R&D ecosystem
Cantai Therapeutics sits inside the Philadelphia region R&D ecosystem in the Global R&D Labs Directory.
Related
Questions and answers
What does Cantai Therapeutics do?
Cantai Therapeutics is classed in biotechnology in its filings with the US Securities and Exchange Commission.
How much has Cantai Therapeutics raised?
At least $4.2m, according to its Form D filings with the US Securities and Exchange Commission.
Where is Cantai Therapeutics based?
Cantai Therapeutics is headquartered in Philadelpia, United States.
When was Cantai Therapeutics founded?
Cantai Therapeutics was founded in 2023.
Source record: SEC EDGAR (Form D filings).
© 311 Institute 2026. Facts from the official sources linked on this page. The selection, classification and links are the proprietary work of the 311 Institute, protected by copyright and database rights.